ANI Pharmaceuticals vs Axsome Therapeutics
ANI Pharmaceuticals is the larger business, with $883m of revenue in fiscal 2025 against $638m for Axsome Therapeutics (1.4 times as much). Axsome Therapeutics grew faster (65.5% against 43.8%). ANI Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 8.9% against -28.7%.
| Latest fiscal year | ANI PharmaceuticalsANIP, 2025 | Axsome TherapeuticsAXSM, 2025 |
|---|---|---|
| Revenue | $883m | $638m |
| Revenue growth | 43.8% | 65.5% |
| Net income | $78.3m | −$183m |
| Operating margin | — | -26.1% |
| Net margin | 8.9% | -28.7% |
| Return on equity | 16.6% | — |
| Free cash flow | $171m | −$93.9m |
| Cash | $286m | $323m |
| Total debt | $309m | $188m |
| Debt to equity | — | 212.6% |
| Dividend per share | — | — |
| Dividend yield | 0.0% | — |
| Share buybacks | $12.2m | — |
| Employees | 970 | — |
| Market value | $1.61bn | $7.38bn |
| Price vs our value range | Below our value range | — |
| Moat score | 45 (Weak) | — |
| Insider trades, 12 months | 0 buys, 50 sales | 0 buys, 33 sales |